US5525464A
(en)
|
1987-04-01 |
1996-06-11 |
Hyseq, Inc. |
Method of sequencing by hybridization of oligonucleotide probes
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
US5700637A
(en)
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
US6054270A
(en)
|
1988-05-03 |
2000-04-25 |
Oxford Gene Technology Limited |
Analying polynucleotide sequences
|
US5871928A
(en)
|
1989-06-07 |
1999-02-16 |
Fodor; Stephen P. A. |
Methods for nucleic acid analysis
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5800992A
(en)
|
1989-06-07 |
1998-09-01 |
Fodor; Stephen P.A. |
Method of detecting nucleic acids
|
US5744101A
(en)
|
1989-06-07 |
1998-04-28 |
Affymax Technologies N.V. |
Photolabile nucleoside protecting groups
|
ATE262374T1
(de)
|
1991-11-22 |
2004-04-15 |
Affymetrix Inc |
Kombinatorische strategien für polymersynthese
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
US5795716A
(en)
|
1994-10-21 |
1998-08-18 |
Chee; Mark S. |
Computer-aided visualization and analysis system for sequence evaluation
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
US20020065296A1
(en)
|
1999-01-13 |
2002-05-30 |
Bayer Corporation |
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
|
CA2359244C
(en)
|
1999-01-13 |
2013-10-08 |
Bayer Corporation |
.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
SK287401B6
(sk)
|
1999-11-05 |
2010-09-07 |
Astrazeneca Ab |
Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
|
US20020010203A1
(en)
|
1999-12-22 |
2002-01-24 |
Ken Lipson |
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
|
NZ520640A
(en)
|
2000-02-15 |
2005-04-29 |
Upjohn Co |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
DK2311825T3
(en)
|
2000-12-21 |
2016-01-18 |
Novartis Ag |
Pyrimidinamines AS ANGIOGENESEMODULATORER
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
ATE345130T1
(de)
|
2001-12-03 |
2006-12-15 |
Bayer Pharmaceuticals Corp |
Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
|
SE0104164L
(sv)
|
2001-12-11 |
2003-06-12 |
Ericsson Telefon Ab L M |
Högspännings-mos-transistor
|
NO317200B1
(no)
|
2002-08-09 |
2004-09-13 |
Best Practice Deployment As |
System for trafikkopplaering i et kjoretoy
|
WO2004029287A2
(en)
|
2002-09-27 |
2004-04-08 |
Oridis Biomed Forschungs- Und Entwicklungs Gmbh |
Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
|
KR20060031809A
(ko)
*
|
2003-06-09 |
2006-04-13 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
암 치료 및 진단용 조성물 및 방법
|
EP1673085B1
(en)
|
2003-09-26 |
2011-11-09 |
Exelixis, Inc. |
C-met modulators and methods of use
|
GB0411378D0
(en)
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
WO2006138275A2
(en)
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
CN101506351A
(zh)
*
|
2005-10-21 |
2009-08-12 |
拜尔健康护理有限责任公司 |
用于癌症预测和预后及监测癌症治疗的方法
|
CA2627873A1
(en)
|
2005-10-31 |
2007-05-10 |
Scott Wilhelm |
Treatment of cancer with sorafenib
|
US8329408B2
(en)
|
2005-10-31 |
2012-12-11 |
Bayer Healthcare Llc |
Methods for prognosis and monitoring cancer therapy
|
WO2008008733A2
(en)
|
2006-07-10 |
2008-01-17 |
Elan Pharma International Ltd. |
Nanoparticulate sorafenib formulations
|
MX2009002936A
(es)
|
2006-09-19 |
2009-04-01 |
Novartis Ag |
Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
|
ES2670423T3
(es)
*
|
2007-07-25 |
2018-05-30 |
Eisai R&D Management Co., Ltd. |
Inhibidores de multicinasas para uso en el tratamiento de cáncer
|
US20090062347A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched axitinib
|
US20090062368A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
AU2008299703C1
(en)
|
2007-09-10 |
2013-09-05 |
Cipla Limited |
Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process
|
AU2008304756B8
(en)
|
2007-09-26 |
2015-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-IL-6 receptor antibody
|
WO2009054004A2
(en)
|
2007-10-22 |
2009-04-30 |
Natco Pharma Limited |
Process for the preparation of sorafenib
|
EP2253629A1
(en)
|
2007-11-21 |
2010-11-24 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
|
US20100256392A1
(en)
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
JP2011512396A
(ja)
|
2008-02-21 |
2011-04-21 |
ジェネリクス・(ユーケー)・リミテッド |
新規な多形およびその調製方法
|
WO2009106825A1
(en)
|
2008-02-27 |
2009-09-03 |
Cipla Limited |
Polymorphs of sorafenib and salts thereof
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
EP2142507A1
(en)
|
2008-03-06 |
2010-01-13 |
Sicor, Inc. |
Process for the preparation of sorafenib and salts thereof
|
JP2011516488A
(ja)
|
2008-03-31 |
2011-05-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
スニチニブ及びその塩の調製方法
|
CA2724310A1
(en)
|
2008-06-23 |
2009-12-30 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
KR20110036588A
(ko)
|
2008-07-24 |
2011-04-07 |
테바 파마슈티컬 인더스트리즈 리미티드 |
수니티닙 아세테이트 및 이의 다형을 통한 수니티닙 말레이트의 제조 방법
|
US20110301113A1
(en)
|
2008-09-26 |
2011-12-08 |
Concert Pharmaceuticals Inc. |
Pyridineamine derivatives
|
CA2704448A1
(en)
|
2008-09-30 |
2010-04-08 |
Teva Pharmaceutical Industries Ltd. |
Amorphous compositions of sunitinib base and l-malic acid
|
US20110257035A1
(en)
|
2008-10-21 |
2011-10-20 |
Bayer Healthcare Llc |
Identification of signature genes associated with hepatocellular carcinoma
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
EP2366162A1
(en)
*
|
2008-11-18 |
2011-09-21 |
Collabrx, Inc. |
Individualized cancer treatment
|
WO2010135608A1
(en)
*
|
2009-05-20 |
2010-11-25 |
Nodality, Inc. |
Methods for diagnosis, prognosis and methods of treatment
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
CA2768237A1
(en)
|
2009-07-16 |
2011-01-20 |
Glaxo Wellcome Manufacturing Pte Ltd |
Treatment method
|
US20120232102A1
(en)
|
2009-09-30 |
2012-09-13 |
Chun-Fang Xu |
Methods Of Administration And Treatment
|
CN102665756A
(zh)
|
2009-10-01 |
2012-09-12 |
Csl有限公司 |
费城染色体阳性白血病的治疗方法
|
US20120245051A1
(en)
*
|
2009-10-13 |
2012-09-27 |
Rimm David L |
Objective, quantitative method to predict histological subtype in non-small cell lung cancer
|
WO2011050159A1
(en)
|
2009-10-23 |
2011-04-28 |
Glaxo Wellcome Manufacturing Pte Ltd |
Compositions and processes
|
UY33164A
(es)
|
2010-01-06 |
2011-08-31 |
Glaxo Wellcome Mfg Pte Ltd |
Metodo de tratamiento
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
UY33367A
(es)
|
2010-05-05 |
2011-10-31 |
Glaxo Wellcome Mfg Pte Ltd |
Composiciones farmacéuticas y métodos para su elaboración
|
WO2011146458A1
(en)
|
2010-05-18 |
2011-11-24 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
EP2635568B1
(en)
|
2010-11-01 |
2017-08-16 |
Scinopharm (Kunshan) Biochemical Technology Co., Ltd. |
Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
|
US9150547B2
(en)
|
2010-11-29 |
2015-10-06 |
Hetero Research Foundation |
Process for the preparation of pazopanib using novel intermediate
|
WO2012088522A1
(en)
|
2010-12-23 |
2012-06-28 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
WO2012103060A1
(en)
|
2011-01-27 |
2012-08-02 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
US20120214830A1
(en)
*
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
CN102283836B
(zh)
*
|
2011-06-27 |
2013-01-09 |
苏州大学附属第一医院 |
索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
|
JP2014518232A
(ja)
|
2011-06-28 |
2014-07-28 |
バイエル・ヘルスケア・エルエルシー |
ソラフェニブを含有する眼科用局所医薬組成物
|
EP2742154A4
(en)
|
2011-08-08 |
2015-08-12 |
Caris Life Sciences Switzerland Holdings Gmbh |
BIOMARKER COMPOSITIONS AND METHODS
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
RU2014107767A
(ru)
|
2011-09-30 |
2015-11-10 |
Пфайзер Инк. |
Фармацевтические композиции на основе n-метил-2-[3-((е)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]бензамида
|
WO2013090419A1
(en)
|
2011-12-12 |
2013-06-20 |
Stc.Unm |
Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
|
WO2013138522A2
(en)
*
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
WO2015031604A1
(en)
|
2013-08-28 |
2015-03-05 |
Crown Bioscience, Inc. |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|